Access to premium content is restricted to healthcare professionals / registered members. Login with your email address to continue.
Forgot Your Password?
Follow Topic
Bookmark
Coroner reports on benzodiazepine death of vulnerable 45-year-old man in Wales
28 Apr 2025
Following a review the MHRA has published an opinion on the regulatory status of products containing cannabidiol (CBD).
15 Apr 2025
Lawrence Tallon takes over from June Raine at MHRA; Dr Penny Dash is new chair of NHS England.
04 Mar 2025
Nemolizumab (Nemluvio, Galderma) has been approved by the MHRA for the treatment of two skins conditions.
18 Feb 2025
The MHRA has launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies (cancer vaccines).
04 Feb 2025
Over £40m worth of illegal medicines taken out of black market circulation in 2024.
29 Jan 2025
MHRA interim executive director James Pound said: "We proactively take action as information and intelligence is shared with us.”
24 Jan 2025
Leeds manufacturer has been selling lidocaine spray without authorisation
14 Nov 2024
MHRA issues GLP-1 receptor agonist warning to pharmacy teams.
24 Oct 2024
New regulations mean that products with a very short shelf life, and personalised medicines such as gene therapy, can more easily be made in or near a hospital setting
22 Oct 2024
The MHRA approved two “presentations of the adapted vaccine” after they met its standards of safety, quality, and effectiveness.
11 Oct 2024
Elafibranor (Iqirvo) has been approved by the MHRA to treat adult patients with a rare type of liver disease known as primary biliary cholangitis
08 Oct 2024
Fruquintinib stops tumours making new blood vessels, which normally provide the tumour with nutrients and oxygen.
20 Sep 2024
MHRA issues new precautionary advice in wake of Scandinavian study
05 Sep 2024
The MHRA has approved generic versions of raltegravir which reduce the amount of HIV in a patient’s blood when used with other medicines.
22 Jul 2024
Migraine and antiseizure medication topiramate (Topamax) must no longer be prescribed to women and girls unless they fulfil the requirements of a Pregnancy Prevention Programme
24 Jun 2024
